triazoles has been researched along with imatinib mesylate in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Schwetz, BA | 1 |
| Kaplow, R | 1 |
| Decosterd, LA; Duchosal, MA; Gambillara, E; Kovacsovics, T; Laffitte, E; Panizzon, RG; Widmer, N | 1 |
| Colson, YL; Marty, FM; Paul, S | 1 |
| Selleslag, D | 1 |
| Alessandro, R; Colomba, P; Corrado, C; De Leo, G; Flugy, AM; Fontana, S; Giordano, M; Kohn, EC; Santoro, A | 1 |
| Chow, LW; Loo, WT; Toi, M; Yip, AY | 1 |
| Ballman, KV; Bot, B; Buckner, JC; DeMatteo, RP; Hillman, SL; Mandrekar, SJ; Nelson, H; Perez, EA; Sargent, DJ | 1 |
| Alessandro, R; Arlinghaus, R; Corrado, C; Flugy, AM; Fontana, S; Iovino, F; Kohn, EC; Leo, GD; Marfia, A; Raimondo, S; Santoro, A; Stassi, G | 1 |
| Barr, AJ; Elkins, JM; Knapp, S; Salah, E; Ugochukwu, E; von Delft, F | 1 |
| Arioli, F; Borrelli, S; Botta, M; Carraro, F; Colombo, F; Crespan, E; Falchi, F; Filippi, I; Maga, G; Naldini, A; Passarella, D; Scalia, G; Silvani, A | 1 |
| Alessandro, R; Corrado, C; De Leo, G; Flugy, AM; Guggino, G; Karmali, R; Raimondo, S; Taverna, S | 1 |
| Chen, Y; Gao, D; Jiang, Y; Jin, F; Liu, F; Tan, C; Wu, Q | 1 |
| Bonneau, K; Bowler, AD; Chenchik, A; Deininger, MW; Eiring, AM; Gantz, KC; Heaton, WL; Iovino, AJ; Kauffman, M; Khorashad, JS; Kraft, IL; Mason, CC; O'Hare, T; Pomicter, AD; Redwine, HM; Reynolds, KR; Shacham, S; Tantravahi, SK; Ullman, KS; Yu, F; Zabriskie, MS | 1 |
| Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Seker, M; Yildiz, C | 1 |
| Bai, CG; Chen, Y; Chu, XQ; Ding, YH; Li, HY; Li, YT; Meng, FF; Pan, CW; Qu, WZ; Wang, JH; Yang, C; Zhang, Q | 1 |
| Choi, CW; Kang, MH; Kim, DS; Na, YJ; Yoon, SY | 1 |
| Ben-Batalla, I; Bokemeyer, C; Brümmendorf, TH; Carmeliet, P; Clark, RE; Erdmann, R; Ernst, T; Helgason, GV; Hochhaus, A; Holyoake, TL; Jørgensen, H; Koschmieder, S; Loges, S; Mitchell, R; Mitra, S; Pantel, K; Rankin, S; Schafhausen, P; Schultze, A; Vandenberghe, P; Velthaus, JL; von Amsberg, G | 1 |
| Antonescu, CR; Balachandran, VP; Bowler, TG; Cross, JR; DeMatteo, RP; Liu, M; Loo, JK; Medina, BD; Moral, AJ; Param, NJ; Rossi, F; Vitiello, GA; Zeng, S; Zhang, JQ; Zhao, JN | 1 |
| Andersen, JL; Armstrong, SA; Bradner, JE; Chipashvili, O; Demetri, GD; Hagan, T; Hemming, ML; Lawlor, MA; Raut, CP; Scott, TG; Sicinska, E | 1 |
| Beaver, LP; Clair, PM; Deininger, MW; Eiring, AM; Hare, TO; Heaton, WL; Mason, CC; Pomicter, AD; Senina, A; Shacham, S; Than, H; Yan, D | 1 |
| Jiao, B; Li, D; Liao, L; Liu, M; Liu, P; Ren, R; Wang, P; Xia, Z; Xiao, X; Zhang, X | 1 |
| Kang, KW; Kim, BS; Kim, JH; Lee, BH; Lee, SJ; Park, Y | 1 |
1 review(s) available for triazoles and imatinib mesylate
| Article | Year |
|---|---|
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
1 trial(s) available for triazoles and imatinib mesylate
| Article | Year |
|---|---|
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Evaluation; Female; Humans; Imatinib Mesylate; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Pilot Projects; Piperazines; Postmenopause; Pyrimidines; Signal Transduction; Triazoles | 2008 |
21 other study(ies) available for triazoles and imatinib mesylate
| Article | Year |
|---|---|
From the Food and Drug Administration.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Arthritis, Psoriatic; Benzamides; Chemical and Drug Induced Liver Injury; Cyclohexanones; Enzyme Inhibitors; Etanercept; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoglobulin G; Infant; Liver Failure; Nitrobenzoates; Orphan Drug Production; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Triazoles; Tyrosinemias; United States; United States Food and Drug Administration | 2002 |
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
Topics: Adult; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Benzamides; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Eruptions; Drug Interactions; Enzyme Inhibitors; Exanthema; Humans; Imatinib Mesylate; Irritants; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Fungal; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Triazoles; Voriconazole | 2005 |
Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Bone Marrow Transplantation; Cefepime; Cephalosporins; Combined Modality Therapy; Cunninghamella; Daunorubicin; Drug Resistance, Multiple, Fungal; Female; Humans; Imatinib Mesylate; Immunocompromised Host; Lung Diseases, Fungal; Middle Aged; Neutropenia; Piperazines; Pneumonectomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Transplantation Conditioning; Triazoles; Vancomycin; Vincristine; Voriconazole; Zygomycosis | 2006 |
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B.
Topics: Abscess; Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Foot Dermatoses; Fusarium; Humans; Imatinib Mesylate; Immunocompromised Host; Liposomes; Male; Middle Aged; Muscular Diseases; Onychomycosis; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Reoperation; Rituximab; Teniposide; Triazoles; Voriconazole | 2006 |
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Molecular Probes; Phosphotyrosine; Piperazines; Pyrimidines; ras Proteins; Triazoles | 2008 |
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Piperazines; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Oxidation-Reduction; Piperazines; Pyrimidines; Reactive Oxygen Species; Triazoles | 2011 |
Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.
Topics: Amino Acid Motifs; Benzamides; Crystallography, X-Ray; Humans; Imatinib Mesylate; Models, Molecular; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Triazoles | 2011 |
N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzamides; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; STAT5 Transcription Factor; Structure-Activity Relationship; Triazoles | 2011 |
Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Exosomes; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Interleukin-8; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neovascularization, Pathologic; Orotic Acid; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Imatinib Mesylate; K562 Cells; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Niacinamide; Piperazines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; Pyrrolidines; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Topics: Active Transport, Cell Nucleus; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exportin 1 Protein; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Gene Library; Humans; Hydrazines; Imatinib Mesylate; K562 Cells; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; ran GTP-Binding Protein; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Signal Transduction; Triazoles; Tumor Stem Cell Assay | 2015 |
Effect of imatinib on growth of experimental endometriosis in rats.
Topics: Anastrozole; Angiogenesis Inhibitors; Animals; Aromatase Inhibitors; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Imatinib Mesylate; Nitriles; Ovarian Follicle; Peritoneal Diseases; Peritoneum; Proto-Oncogene Proteins c-kit; Rats; Transplantation, Autologous; Triazoles; Vascular Endothelial Growth Factor A | 2016 |
Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Molecular Structure; Oxadiazoles; Structure-Activity Relationship; Triazoles | 2016 |
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Iron Chelating Agents; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction; Triazoles | 2016 |
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridazines; Receptor Protein-Tyrosine Kinases; Small Molecule Libraries; Triazoles | 2017 |
Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrazones; Imatinib Mesylate; Metabolic Networks and Pathways; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Protein Kinase Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Topics: Animals; Apoptosis; Azepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; HEK293 Cells; Humans; Imatinib Mesylate; Mice; Mice, Nude; Protein Domains; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-kit; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzamides; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; Radiation Chimera; Random Allocation; RNA Interference; RNA, Small Interfering; Signal Transduction; Triazoles | 2020 |
CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Interleukin-8; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Interleukin-8B; Triazoles; Young Adult | 2021 |